




Clinical and virological characteristics of hospitalised COVID‑19 
patients in a German tertiary care centre during the first wave 
of the SARS‑CoV‑2 pandemic: a prospective observational study
Charlotte Thibeault1 · Barbara Mühlemann2,3 · Elisa T. Helbig1 · Mirja Mittermaier1,4 · Tilman Lingscheid1 · 
Pinkus Tober‑Lau1 · Lil A. Meyer‑Arndt5,6 · Leonie Meiners2,3 · Paula Stubbemann1 · Sascha S. Haenel1 · 
Laure Bosquillon de Jarcy1,2,3 · Lena Lippert1 · Moritz Pfeiffer1 · Miriam S. Stegemann1 · Robert Roehle4,7 · 
Janine Wiebach4,7 · Stefan Hippenstiel1 · Thomas Zoller1 · Holger Müller‑Redetzky1 · Alexander Uhrig1 · 
Felix Balzer8 · Christof von Kalle4 · Norbert Suttorp1,9 · Terry C. Jones2,3,10 · Christian Drosten2,3 · 
Martin Witzenrath1,9 · Leif E. Sander1 · Pa‑COVID Study Group · Victor M. Corman2,3 · Florian Kurth1,11,12 
Received: 21 December 2020 / Accepted: 23 February 2021 
© The Author(s) 2021
Abstract
Purpose Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires 
detailed knowledge of clinical and virological disease trajectories. The purpose of this work was to identify risk factors 
associated with need for invasive mechanical ventilation (IMV), to analyse viral kinetics in patients with and without IMV 
and to provide a comprehensive description of clinical course.
Methods A cohort of 168 hospitalised adult COVID-19 patients enrolled in a prospective observational study at a large 
European tertiary care centre was analysed.
Results Forty-four per cent (71/161) of patients required invasive mechanical ventilation (IMV). Shorter duration of symp-
toms before admission (aOR 1.22 per day less, 95% CI 1.10–1.37, p < 0.01) and history of hypertension (aOR 5.55, 95% 
CI 2.00–16.82, p < 0.01) were associated with need for IMV. Patients on IMV had higher maximal concentrations, slower 
decline rates, and longer shedding of SARS-CoV-2 than non-IMV patients (33 days, IQR 26–46.75, vs 18 days, IQR 
16–46.75, respectively, p < 0.01). Median duration of hospitalisation was 9 days (IQR 6–15.5) for non-IMV and 49.5 days 
(IQR 36.8–82.5) for IMV patients.
Conclusions Our results indicate a short duration of symptoms before admission as a risk factor for severe disease that merits 
further investigation and different viral load kinetics in severely affected patients. Median duration of hospitalisation of IMV 
patients was longer than described for acute respiratory distress syndrome unrelated to COVID-19.
Keywords Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) · Coronavirus disease 2019 (COVID-19) · 
Viral concentration · COVID-19 nucleic acid testing · Respiratory distress syndrome · Mechanical ventilation · Artificial 
respiration · Prospective study · Symptom assessment
Introduction
The ongoing severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) pandemic places an unprecedented burden 
on healthcare systems worldwide. Host factors predictive of 
severe clinical course and adverse outcome in patients with 
coronavirus disease 2019 (COVID-19) include older age, 
male gender, and pre-existing chronic comorbidities [1–6]. 
Several risk scores containing clinical characteristics, labo-
ratory assessments, and biomarkers have been proposed for 
improved patient management and resource allocation [5, 7].
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Reported proportions of hospitalised patients requiring 
invasive mechanical ventilation (IMV) vary considerably 
between 2.3% [8] and 23.6% [2]. In-hospital case fatality 
rates of 20–30% have been described in China, Germany, 
Italy, the UK, and the US [1, 6, 9–11]. In Germany, short-
ages of inpatient beds and intensive care unit (ICU) capacity 
were largely avoided during the first pandemic wave, con-
tributing to a comparatively low overall case fatality rate 
[1, 12].
Here, we report clinical characteristics, laboratory and 
virological parameters, clinical course, and outcome of 168 
COVID-19 patients included in a prospective observational 
cohort study conducted at Charité-Universitätsmedizin 
Berlin, Germany. The study was designed for deep clinical, 
molecular, and immunological phenotyping of COVID-19 
[13–17].
The data reflect the situation in a tertiary care referral 
centre for the treatment of patients with acute respiratory 
distress syndrome (ARDS), including veno-venous extracor-
poreal membrane oxygenation (vvECMO) therapy, and an 
associated certified weaning centre during the first months of 
the COVID-19 pandemic, before treatment with dexametha-
sone became standard of care [18]. Specific aims of this 
work were to identify risk factors associated with need for 
IMV, to analyse viral kinetics in patients with and without 
IMV, and to provide a comprehensive description of clinical 
course and outcome.
Methods
Study cohort and data collection
Data collection was performed within the Pa-COVID-19 
study, a prospective observational cohort study conducted at 
Charité-Universitätsmedizin Berlin, as described [13]. Adult 
patients admitted between March 1st and June 30th, 2020, 
with PCR-confirmed SARS-CoV-2 infection were included 
if patients or their legal representatives gave informed con-
sent. We recorded epidemiological and demographic data, 
medical history, history of present illness, symptoms, clini-
cal course, treatment, and outcomes upon enrolment and lon-
gitudinally during hospitalisation. The study was approved 
by the ethics committee of Charité-Universitätsmedizin Ber-
lin (EA2/066/20), conducted according to the Declaration of 
Helsinki and Good Clinical Practice principles (ICH 1996) 
and is registered in the German and WHO international 
clinical trials registry (DRKS00021688).
The primary objective of this first analysis of the Pa-
COVID-19 cohort was to identify risk factors and viro-
logical and laboratory parameters associated with need 
for IMV. Comorbidities were classified using the Charlson 
comorbidity Index (CCI) [19]. ARDS was defined according 
to the Berlin definition of ARDS [20]. Sequential Organ 
Failure Assessment (SOFA) score [21] was calculated from 
data recorded in the ICU data management system. The 
following predefined events were assessed in all patients: 
(1) sepsis (defined according to sepsis-3 criteria [22], (2) 
venous thromboembolic events (VTE; pulmonary embolism 
or deep vein thrombosis), (3) neurologic events (haemor-
rhagic/ischaemic stroke, delirium, intensive care unit-
acquired weakness, ICUAW), epileptic seizure, meningitis 
and encephalitis). Treatment was unaffected by participation 
in the study. Patient allocation was performed according to 
structured regional processes [23] and management of criti-
cally ill patients following current guidelines as described 
[24, 25].  Duration of symptoms was only analysed for 
patients with reliable information on symptom onset in the 
patient chart given by patients themselves or relatives.
All laboratory assessments were carried out in accredited 
laboratories at Charité- Universitätsmedizin Berlin. SARS-
CoV-2 viral concentration was measured in respiratory sam-
ples (naso- or oropharyngeal swabs) by real-time RT-PCR 
[26]. Viral concentration is given as  log10 genome copies per 
swab or initial 1 mL sampling buffer.
Statistical analyses
Distribution of continuous variables was summarised by 
median and interquartile range (IQR) values or mean and 
standard deviation (SD), as appropriate. The differences 
of continuous variables between groups were examined 
by Welch’s t test or, in absence of normal distribution, by 
Mann–Whitney U test. Categorical variables were compared 
using Chi-square tests. For all analyses, complete cases were 
used for the respective evaluation.
We conducted a multiple logistic regression with “need 
for invasive mechanical ventilation” as a binary dependent 
variable and age, BMI, hypertension, diabetes, and time 
between symptom onset and admission to hospital as inde-
pendent variables. The covariates were chosen taking into 
account current evidence, results from univariate testing, 
and sample size. We performed univariate tests regarding 
all available patient factors and association with organ sup-
port treatment, complications, and outcome. Continuous 
variables were treated as follows: age was categorized in 
accordance with other reports on patients with COVID-19 
[1], BMI and CCI were dichotomized at the median. Patients 
with therapy limitations (Do Not Intubate (DNI) or Do Not 
Resuscitate (DNR) orders) at the respective time point 
were excluded for comparison between non-IMV and IMV 
patients, and for analyses of course-of-organ support and 
mortality. Non-survivors were excluded from comparison 
between short- (< 15 days) or long-term (≥ 15 days) IMV. 
For analysis of SOFA score, scores were extracted from 
electronic patient charts and the highest score per day was 
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included for calculation of means. The neurological compo-
nent of the SOFA score was not taken into consideration due 
to patient sedation and incomplete documentation during 
daily discontinuation of sedation. Patients who died or were 
transferred to other centres were excluded from calculation 
of length of hospital stay. For analyses of routine labora-
tory parameters within 72 h of first admission, first-available 
parameters were included.
We compared viral concentration between non-IMV and 
IMV patients, and regressed viral concentration on the dura-
tion from symptom onset to admission using both the first 
positive RT-PCR result and the RT-PCR with the highest 
viral concentration. For the calculation of viral concentra-
tion decline, we estimated the slope parameter from a linear 
regression of at least four viral concentration measurements 
over time for each patient. If available, the first of at least 
two final negative RT-PCR results was included, in which 
case the viral concentration of the negative RT-PCR was set 
to 2.0 in accordance with the RT-PCR limit of detection and 
sample dilution factor of ~ 20 [26, 27]. We calculated shed-
ding duration as the time from symptom onset to the date of 
the first of at least two final negative RT-PCR results.
Analyses were conducted with R (version 3.6.1), JMP 
(version 14.2.0), and statsmodels (version 0.12.0) in 
Python 3.7.9. A p value < 0.05 indicates statistical signifi-
cance, although all results have to be considered as non-




Between March 1st and June 30th 2020, a total of 347 
adult patients with COVID-19 were hospitalised at Char-
ité-Universitätsmedizin Berlin. This analysis includes 168 
adult patients who consented to participation in the pro-
spective observational study (Fig. 1). Sixty-five per cent 
(110/168) were directly admitted to our centre, whereas 
29.8% (50/168) were referred due to ARDS or other con-
ditions requiring tertiary care. Four per cent (7/168) were 
hospitalised for other reasons and coincidentally diag-
nosed with SARS-CoV-2 infection during routine screen-
ing, and one patient (0.6%) was admitted due to a late 
complication of COVID-19.
Baseline characteristics are shown in Table 1. Median 
patient age was 61  years (IQR 49.3–72), and 66.1% 
(111/168) were male. Median CCI was 3 (IQR 1–4). 
Most prevalent comorbidities were hypertension (53.6%, 
90/168), diabetes (19.6%, 33/168), and chronic pulmonary 
disease (16.7%, 28/168). Median time from symptom onset 
until diagnosis was 4 days (IQR 1–7), and from symptom 
onset until admission to hospital was 6 days (IQR 3–10).
ARDS and organ support treatment
Fifty-two per cent (88/168) of patients developed ARDS. 
One of them was already dependent on long-term 
Fig. 1  Study cohort flowchart. A total of 347 adult patients were hos-
pitalised with COVID-19 during the study period from March 1st 
until June 30th at Charité-Universitätsmedizin Berlin. Of these, 168 
patients could be enrolled in the prospective observational study, 
whereas 179 denied. Among the included patients, 88 had acute res-
piratory distress syndrome (ARDS). One patient with ARDS was 
already invasively ventilated and six of them had DNI/DNR (do not 
intubate/do not resuscitate) orders in place, resulting in 81 patients 
requiring respiratory support. Of those, 71 patients were intubated 
and ten required only high-flow nasal cannula oxygen therapy
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Table 1  Baseline patient characteristics, unadjusted and adjusted odds ratios and 95% confidence intervals for need of mechanical ventilation
All patients Non-IMV IMV Unadjusted OR (95% 
CI); p value Chi-square 
test 
Adjusted OR (95% CI); 
p value 
Total number of 
patients
168 55.9%, 90/161 44.1%, 71/161
Age in years (median, 
(IQR)) 
61 (49.3–72) 59 (42–72) 62 (54–72)
 18–59 46.4%, 78/168 54.4%, 49/90 40.8%, 29/71 Reference group Reference group
 60–69 21.4%, 36/168 15.6%, 14/90 31.0%, 22/71 2.66 (1.18–5.89); 0.02  4.33 (1.07–20.10); 0.05 
 70–79 20.8%, 35/168 21.1%, 19/90 19.7%, 14/71 1.24 (0.54–2.85); 0.60 0.55 (0.14–1.91); 0.36
 ≥ 80 11.3%, 19/168 8.9%, 8/90 8.5%, 6/71 1.26 (0.40–4.02); 0.69 0.26 (0.04–1.54); 0.15
Gender
 Female 33.9%, 57/168 38.9%, 35/90 29.6%, 21/71 Reference group
 Male 66.1%, 111/168 61.1%, 55/90 70.4%, 50/71 1.51 (0.78–2.94); 0.22









 ≥ 30 kg/m2 33.3%, 52/156 28.4%, 23/81 39.1%, 27/69 1.62 (0.81–3.21); 0.16 1.27 (0.46–3.47); 0.63
Major comorbidities
 CCI median, (IQR) 3 (1–4) 2 (0–4) 3 (1–4)
 < 3 49.4%, 83/168 60.0%, 54/90 40.8%, 29/71 Reference group
 ≥ 3 50.6%, 85/168 40.0%, 36/90 59.2%, 42/71 2.17 (1.15–4.09), 0.02
 Hypertension 53.6%, 90/168 42.2%, 38/90 63.4%, 45/71 2.37 (1.25–
4.49); < 0.01 
5.55 (2.00–16.82); < 0.01 
 Diabetes 19.6%, 33/168 13.3%, 12/90 23.9%, 17/71 2.05 (0.90–4.63); 0.08 1.5 (0.42–5.49); 0.53
 Chronic pulmonary 
disease
16.7%, 28/168 13.3%, 12/90 21.1%, 15/71 1.74 (0.77–4.00); 0.19
 Chronic kidney 
disease
13.7%, 23/168 15.6%, 14/90 8.5%, 6/71 0.50 (0.18–1.38); 0.17
 Disorder of lipid 
metabolism
13.7%, 23/168 15.6%, 14/90 9.9%, 7/71 0.79 (0.30–2.10); 0.63
 Cardiac arrhythmia 13.7%, 23/168 13.3%, 12/90 12.7%, 9/71 0.94 (0.37–2.83); 0.90
 Chronic myocardial 
infarction
7.7%, 13/168 3.3%, 3/90 12.7%, 9/71 4.21 (1.09–16.18), 0.03
 Congestive heart 
failure
5.4%, 9/168 4.4%, 4/90 5.6%, 4/71 1.28 (0.30–5.32); 0.73
 Chronic neurological 
disease
9.5%, 16/168 6.7%, 6/90 9.9%, 7/71 1.81 (0.58–5.69); 0.31





2 (1–3) n = 143 2 (0–3) n = 89 2 (1–4) n = 54
 ARB 20.2%, 29/143 15.7%, 14/89 24.1%, 14/58 1.77 (0.77–4.09); 0.18
 ACE-i 18.9%, 27/143 13.5%, 12/89 19.0%, 11/58 1.53 (0.62–3.78); 0.35
 Lipid lowering agents 18.9%, 27/143 15.7%, 14/89 20.7%, 12/58 1.44 (0.61–3.42); 0.44
 Antibiotics last 
90 days
20.2%, 29/143 19.1%, 17/89 20.7%, 12/58 1.09 (0.47–2.53); 0.83
Number of symptoms 
median (IQR), avail-
able n
3 (2–4), n = 163 3 (2–5), n = 85 3 (2–4), n = 71
 Fever 63.8%, 104/163 69.4%, 59/85 63.4%, 45/71
 Dry cough 53.4%, 87/163 57.6%, 49/85 52.1%, 37/71
 Dyspnea 48.5%, 79/163 42.4%, 36/85 53.5%, 38/71
 Fatigue 27.6%, 45/163 29.4%, 25/85 25.4%, 18/71
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intermittent invasive ventilation and six had DNI orders 
in place. Of the remaining 81 patients with ARDS, 87.6% 
(71/81) required IMV whereas 12.3% (10/81) could be 
managed with HFNC oxygen only (Fig. 1). Median time 
from hospital admission to intubation was 2 days (IQR 
0–4). Among all patients without therapeutic limitations, 
44.1% (71/161) required IMV, 9.9% (16/161) could be 
treated with HFNC oxygen only, 24.2% (39/161) required 
oxygen via nasal prongs, and 22% (35/161) were not in 
need of supplemental oxygen.
Age between 60 and 69  years as compared to 18 to 
59 years (adjusted OR 4.33, 95% CI 1.07–20.10, p = 0.05) 
and pre-existing hypertension (adjusted OR 5.55, 95% CI 
2.00–16.82, p < 0.01) were independent risk factors for 
IMV requirement in multivariable analysis. Requirement for 
IMV increased with shorter duration of symptoms before 
hospital admission (adjusted OR 1.22 per day less, 95% CI 
1.10–1.37, p < 0.01, Table 1). To account for the possible 
impact of less accurate information on duration of symptoms 
in patients transferred from other hospitals, we performed a 
sensitivity analysis by excluding patients with > 1 day stay in 
an external hospital (n = 45). This analysis yielded a similar 
result of increased need of IMV with shorter duration of 
symptoms (adjusted OR 1.18 95% CI 1.04–1.35, p = 0.015).
Seventy-nine per cent (56/71) of all intubated patients 
required long IMV. Need for long IMV was associated 
Bold values indicate statistically significant difference between IMV and non-IMV patients
Patients with therapy limitations were excluded from comparison and statistical analysis of IMV versus non-IMV patients. Asymptomatic 
patients were excluded from analyses of symptom characterisation. Independent variables incorporated into the multiple logistic regression 
model: Age, BMI, hypertension, diabetes, and length between symptom onset and admission
IMV invasive mechanical ventilation, OR odds ratio, CI confidence interval, IQR interquartile range, BMI body mass index, CCI Charlson 
comorbidity index, ARB angiotensin II receptor blockers, ACE-i angiotensin-converting enzyme inhibitor, ARDS acute respiratory distress syn-
drome
a Inverse adjusted OR and confidence interval
Table 1  (continued)
All patients Non-IMV IMV Unadjusted OR (95% 
CI); p value Chi-square 
test 
Adjusted OR (95% CI); 
p value 
 Diarrhoea 12.9%, 21/163 17.7%, 15/85 8.5%, 6/71
 Vomitus 7.4%,12/163 9.4%, 8/85 5.6%, 4/71
 Stomach pain 4.9%, 8/163 7.1%, 6/85 2.8%, 2/71
 Impaired conscious-
ness
1.8%, 3/163 1.2%, 1/85 2.8%, 2/71
 Olfactory/gustatory 
dysfunction





65.5%, 110/168 87.8%, 79/90 39.4%, 28/71
 Referral from other 
hospitals
29.8%, 50/168 5.5%, 5/91 60.6%, 43/71
 a) ARDS 17.9%, 30/168 42.3%, 30/71
 b) Other critical medi-
cal condition 
3.6%, 6/168 1.1%, 1/91 7.0%, 5/71
 c) Other reason for 
referral 
8.3%, 14/168 4.4%, 4/91 11.3%, 8/71
 Other primary reason 
for admission
4.2%, 7/168 5.5%, 5/91 2.8%, 2/71
 Late admission 0.6%, 1/168 1.1%, 1/91 –
Time between symptom 
onset and admission 
in days median (IQR), 
available n
6 (3–10), n = 131 8 (5–12) n = 72 5 (2–7) n = 55 1.22 (1.10–1.37)a; < 0.01
 ≤ 5 days 41.2%, 54/131 27.8%, 20/72 56.4%, 31/55 3.36, (1.60–
7.10), < 0.01
 > 5 days 58.8%, 77/131 72.2%, 52/72 43.6%, 24/55 Reference group
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with a short (≤ 1 day) duration from admission until intu-
bation (20.0% (3/15) of patients with short IMV vs 53.6% 
(30/56) patients with long IMV, unadjusted OR (uOR) 
4.6, 95% CI 1.17–18.16, p = 0.02). Other factors associ-
ated with long IMV were transferral from other centres 
(28.6% (4/14) of patients with short IMV were transferred 
vs 69.6% (39/56) of patients with long IMV, uOR 5.73, 
95% CI: 1.58–20.87, p < 0.01), a higher total mean SOFA 
score during the second week after initial admission (8.4, 
95% CI 5.83–10.9 in patients with short IMV vs 11.2, 
95% CI 10.1–12.3, p = 0.04 in patients with long IMV) as 
well as differences in SOFA score components (coagula-
tion, hepatic impairment; for details see Supplementary 
Table 1).
IMV patients had a significantly higher risk of death 
from COVID-19 compared to non-IMV patients (1.1% 
(1/90) of non-IMV patients died vs 29.6% (21/71) of IMV 
patients, uOR 37.38, 95% CI 4.88–286.26, p < 0.01). 
Sixty-three per cent (44/70) of IMV patients underwent 
tracheotomy at a median time of 15 days (IQR 12–20) 
from intubation. Weaning from IMV was successfully con-
cluded in 76.0% (38/50) of surviving IMV patients after a 
median of 42 days (IQR 16–66) from intubation. Eighteen 
per cent (9/50) of patients remained dependent on inter-
mittent IMV and 6.0% (3/50) on long-term oxygen therapy 
(LTOT) upon discharge or transferral.
Thirty-one per cent (22/71) of all IMV patients required 
vvECMO (hereafter termed “ECMO”) treatment. ECMO 
was initiated a median of 9 days (IQR 5.3–18.5) from 
intubation and continued for a median of 18 days (IQR 
7.8–35.5). All ECMO patients required haemodialy-
sis, 86.4% (19/22) underwent tracheotomy, 50% (11/22) 
had a VTE, and 50% (11/22) died. Seventy-five per cent 
(53/71) of all patients with IMV and all (22/22) patients on 
ECMO received proning therapy. Details of the subgroup 
of patients receiving proning therapy have been reported 
elsewhere [25].
Haemodialysis was initiated in 30.4% (51/168) of 
patients, and in 66.2% (47/71) of patients with IMV. Hae-
modialysis was initiated after a median of 8 days (IQR 
4.5–14 days) following hospital admission and 5 days (IQR 
2–8.8 days) after intubation. Thirty-eight per cent (18/47) 
of IMV patients with haemodialysis died. For details on 
tracheotomy, ECMO and haemodialysis see Supplementary 
Table 2.
As no evidence of efficacy of antiviral and anti-inflam-
matory treatments was available at the time, these were not 
used systematically and only in a small subgroup of patients 
of this cohort. Seventeen per cent (29/168) of all patients 
received corticosteroids in ≥ 40 mg prednisolone equivalent 
for ≥ 1 day. For details see Supplementary Table 3.
Virological and routine laboratory data
Viral concentration data were available for 166/168 patients. 
On average, each patient had seven RT-PCR tests (SD: 
5.3, min = 1, max = 29, including positive and negative 
result) from the day of symptom onset (or 10 days from 
first admission, if the date of symptom onset was not avail-
able) to the end of hospitalisation, with tests performed 
every 8.4 days on average (SD: 8.8). Eighty-six patients 
had two final negative RT-PCR tests at the end of the dis-
ease course. Median first-measured viral concentration dif-
fered by 0.68  log10 viral copies between IMV and non-IMV 
patients (5.9, IQR 4.68–7.28 vs 5.22  log10 viral copies, 
IQR 4.49–7.28, respectively; p = 0.12, Fig. 2a), and median 
highest viral concentration by 1.19  log10 viral copies (6.7, 
IQR 5.35–7.62 vs 5.51  log10 viral copies, IQR 4.7–7.62, 
respectively; p = 0.02, Fig. 2b). Decline of viral concentra-
tion (Supplementary Fig. 1) was significantly slower in IMV 
versus non-IMV patients (– 0.13, IQR – 0.19 to – 0.08 vs 
– 0.22  log10 viral concentration decrease / day, IQR – 0.3 
to – 0.08, respectively; p < 0.01) (Fig. 2c, Supplementary 
Fig. 2a–d). The duration of shedding was significantly longer 
in IMV patients than in non-IMV patients (median 33, IQR 
26–46.75 vs 18 days, IQR 16–46.75, p < 0.01) (Fig. 2d). We 
found no association between viral concentration and the 
duration from symptom onset to admission and no differ-
ence in first or in highest viral concentrations in patients 
requiring long versus short IMV (Supplementary Fig. 3a–d, 
Supplementary Table 1).
A statistically significant difference between non-IMV 
and IMV patients was observed in the levels of C-reactive 
protein (CRP), procalcitonin (PCT), Interleukin-6 (IL-6), 
lactate dehydrogenase, ferritin, leukocyte count, lympho-
cyte count, neutrophil-to-lymphocyte ratio, creatinine, urea, 
aspartate aminotransferase, creatine kinase, N-terminal pro-
hormone of brain natriuretic peptide, and troponin (Sup-
plementary Table 4). The course of 12 routine laboratory 
parameters over time in non-IMV and IMV patients is shown 
in Fig. 3.
Complications during treatment
Eighteen per cent (31/168) of patients developed sepsis. 
Occurrence of sepsis was associated with organ replacement 
therapies, but not with patient-related risk factors (Supple-
mentary Table 5). The first sepsis episode occurred after 
a median of 16 days (IQR 8–21) from hospital admission 
and 11.5 days (IQR 3–18.3 days) from intubation. In 15/31 
(48.4%) of patients with sepsis, ECMO was initiated dur-
ing or soon after occurrence of sepsis (median time from 
occurrence of sepsis and initiation of ECMO, 0 days, IQR 
0–6.25 days).
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Nineteen per cent (32/168) of patients were diagnosed 
with at least one VTE. Due to evidence for increased risk of 
thromboembolic events in COVID-19 (36), therapeutic or 
semitherapeutic anticoagulation was introduced in all criti-
cally ill patients from April 2020. A quarter of VTEs (8/32) 
occurred without anticoagulatory treatment, 18.8% (6/32) 
under prophylactic anticoagulation, and 46% (15/32) under 
therapeutic anticoagulation. In 9.3% (3/32) of patients, VTE 
was diagnosed at autopsy and anticoagulation status at onset 
was unclear.
Twenty-four per cent of patients (41/168) had at least one 
neurologic event during hospitalisation, including haemor-
rhagic stroke (9/41, 22%), ischaemic stroke (3/41, 7.3%), 
delirium (17/41, 41.5%), ICUAW (17/41, 41.5%), and epi-
leptic seizure (3/41, 7.3%). Details of sepsis episodes, VTE 
and neurologic events are shown in Supplementary table 5.
Outcome
Median time of hospital stay was 14 days (IQR 7–35) for 
all, 9 days (IQR 6–15.5) for non-IMV, and 49.5 days (IQR 
36.8–82.5) for IMV patients.
Seventeen per cent (29/168) of all patients died. Of all 
patients without therapy limitations (DNR/DNI), 13.6% 
(22/161) died, 8.7% (14/161) were transferred to other 
centres, and 77.6% (125/161) were discharged. Median 
time from first hospitalisation until death was 33 days 
(IQR 16–98).
In univariate analyses, CCI ≥ 3 (uOR 4.35, 95% CI 
1.52–12.45, p < 0.01), short duration of symptoms (uOR 
6.08, 95% CI 1.88–19.68, p < 0.01), occurrence of sepsis 
(uOR 16.47, 95% CI 5.85–46.5, p < 0.01), occurrence of 
VTE (uOR 7.58, 95% CI 2.88–19.97, p < 0.01) and higher 
SOFA score during 1st and 2nd week after intubation 
were associated with death. There was a difference in the 
median first and highest viral concentration between sur-
vivors and non-survivors (6.84, IQR 4.99–7.91 vs 5.38, 
IQR 4.54–7.91, p = 0.05; and 7.14, IQR 5.39–7.91 vs 5.86, 
Fig. 2  Comparison of viral concentration between patients with 
invasive mechanical ventilation (IMV) and those without IMV (non-
IMV). a First-measured viral concentration: Median  log10 viral con-
centration and (IQR) are 5.9 (4.68–7.28) for IMV patients and 5.22 
(4.49–7.28) for non-IMV patients. b Highest viral concentration: 
Median  log10 viral concentrations and (IQR) are 6.7 (5.35–7.62) for 
IMV patients and 5.51 (4.7–7.62) for non-IMV patients. c Differences 
in the slopes of  log10 viral concentration decline rates were estimated 
using a linear regression of viral concentration from the full disease 
course of a patient and days since symptom onset (n = 63) or admis-
sion (n = 10) for patients with and without IMV. Only patients with at 
least four viral concentration measurements were included. d Dura-
tion from symptom onset to the first of at least two final negative 
RT-PCR results for ventilated and non-ventilated patients. Median 
33  days (IQR: 26–46.75) for IMV vs 18  days (IQR: 16–46.75) for 
non-IMV patients, p < 0.01) Pairwise comparisons were performed 
using a Mann–Whitney U test. Grey horizontal lines indicate the 
median
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IQR 4.77–7.91, p = 0.04, respectively) (Supplementary 
Table 6).
Of all discharged or transferred patients, 6.5% (9/139) 
still required IMV, 2.9% (4/139) LTOT, and 1.4% (2/139) 
new haemodialysis.
Discussion
We analysed a detailed clinical and virological dataset from 
a prospective observational cohort of COVID-19 patients 
hospitalised in a tertiary, ECMO/ARDS referral and wean-
ing centre in Germany during the first wave of the SARS-
CoV-2 pandemic, before dexamethasone became standard 
of care.
We report a short duration of symptoms before clinical 
deterioration as a risk factor for severe COVID-19. Second, 
our results indicate that severely ill patients have higher 
maximal viral concentrations and a slower decline of viral 
concentration compared to mildly affected patients. Third, 
we describe a comparatively long duration of inpatient treat-
ment for patients with IMV, largely exceeding that described 
for non-COVID-19 ARDS patients.
Rapid clinical deterioration—as reflected by short dura-
tion of symptoms before hospital admission—is a highly 
relevant risk factor for both need of IMV in a multivariable 
risk model and death in univariate analyses in our cohort. A 
shorter duration of symptoms was not associated with higher 
initial viral concentration. There was also no difference in 
initial viral concentration in more severely ill patients, i.e., 
those requiring IMV, compared to mildly ill patients. Yet, we 
found a significant increase of inflammatory markers such as 
CRP, PCT, and IL-6 at presentation and over time in IMV 
compared to non-IMV patients. Moreover, IMV patients had 
higher maximal concentrations, a slower decline as well as 
longer duration of shedding of SARS-CoV-2 compared to 
non-IMV patients. Higher maximal viral concentrations 
were also found in patients who died, compared to survivors.
These findings underline that the early inflammatory 
host response to SARS-CoV-2 determines the course of 
disease more than pathogen factors such as initial SARS-
CoV-2 RNA concentration [2, 28, 29]. A short duration 
of symptoms before admission possibly reflects a rapid 
increase of the level of inflammation and might serve as an 
easy to assess prognostic factor for clinical deterioration, 
a finding that merits further exploration [30]. During the 
Fig. 3  a–l Comparison of laboratory parameters during the course 
of disease in IMV (red) versus non-IMV patients (blue). X-axis: days 
post-admission. The boxes and lines are median 25th and 75th per-
centiles, Whiskers indicate the 1st and 99th percentile. A Welch’s t 
test was used: *p < 0.05, **p < 0.01
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further course of COVID-19, severe disease is character-
ised by the inability to rapidly reduce viral particles. A 
possible explanation for this phenotype—rapid deterio-
ration after symptom onset, high inflammatory markers, 
and lack of efficient clearing of viral particles—might be 
the various kinds of immune dysregulation, as reported 
by our group and others [15, 31]. Conflicting results have 
been published regarding the association between clini-
cal severity and viral concentration for SARS-CoV-2 so 
far [32–36]. This could possibly be explained by a rather 
unbalanced proportion of mildly and severely affected 
patients in the respective studies as compared to our cohort 
[35]. However, it is undetermined whether higher maximal 
viral concentration and longer duration of shedding are a 
possible cause or an indicator of more severe organ dam-
age and disease.
Although a remarkable proportion (29.8%) of patients 
was transferred to our center due to severe ARDS, and over-
all 44.1% needed IMV, we report a comparatively low in-
hospital mortality of 13.6% in patients without limitations 
of therapy. In comparison, Karagiannadis et al. reported in-
hospital mortality of 22.2% [1] and Rieg et al. of 23.9% [37] 
in cohorts from Germany with 17.2% [1] and 32.9% [37] 
ventilated patients, respectively. Of note, our data show a 
high median length of hospital stay of 49.5 days for patients 
requiring IMV. By comparison, the median length of hos-
pital stay for non-COVID ARDS patients was 17 days in a 
recent global multi-centre prospective study [38]. There is 
growing evidence that the length of IMV-, ICU-, and inpa-
tient treatment of patients with COVID-19 ARDS exceeds 
that of patients with ARDS unrelated to COVID-19 [30, 
37]. Despite the long median duration of hospital stay, a 
considerable percentage of patients could not successfully 
be weaned off the ventilator (18%), and 6% required ongoing 
oxygen therapy following discharge. The mere number of 
deceased patients therefore depicts the burden of disease of 
COVID-19 only very incompletely, particularly with respect 
to long-term morbidity. The prospective approach of our 
study will allow us to evaluate long-term complications in 
the aftermath of COVID-19.
Prospective observational studies are often hampered by 
selection of patients with relatively mild disease courses 
due to need for informed consent. The high proportion of 
severely affected patients in this study cohort indicates that 
this specific selection bias does not apply to our data. On 
the contrary, it is rather the selection of severely ill patients 
referred for ARDS management that might have led to a 
bias. On the other hand, one-fifth of patients was only mildly 
affected and did not require oxygen therapy, representing a 
sub-cohort admitted for clinical observation or due to lack-
ing the possibility of self-isolation. Other major limitations 
of our work are its monocentricity and small sample size.
Our data give a comprehensive description of the clinical 
course, virological characteristics, organ support treatment, 
complications, and outcome of a representative cohort of 
patients in an unrestricted tertiary care healthcare setting 
with comparatively low mortality. The reported findings will 
be of value for comparison of clinical courses in the dexa-
methasone era and for sample size calculation for interven-
tional studies in similar settings.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s15010- 021- 01594-w.
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